{"prompt": "['2016N277425_01', 'CONFIDENTIAL', '2018N377698_0', '201749', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'continue in the study and the need for alternative therapy.', 'Severe hepatic impairment', 'UMEC has not been studied in severe hepatic impairment.', 'Exclusion criterion states that subjects with severe hepatic', 'impairment should only be included if, in the opinion of the', 'study physician, the benefit outweighs the risk.', 'Pregnancy/Lactation', 'There is no experience to date of pregnancy during the use', 'The study inclusion criteria ensure that female subjects', 'of UMEC.', 'enrolled, who are of Child bearing potential, have a', 'negative pregnancy test at screening, and agree to a', 'reliable contraceptive method, used consistently and', 'correctly (i.e. in accordance with the approved product', 'label and the instructions of the physician for the duration', 'of the study). Exclusion criteria states - Pregnancy:', 'Women who are pregnant or lactating or are planning on', 'becoming pregnant during the study.', 'Study Procedures', 'Spirometry procedures', 'This may cause difficulty breathing, changes in pulse rate', 'Subjects will be monitored during the procedure for these', 'and blood pressure, coughing, wheezing, chest tightness or', 'effects and spirometry will be discontinued should these', 'fainting.', 'occur.', 'ECG lead placement', 'This may cause skin irritation.', 'It may be necessary to have small patches (about a', 'centimetre in diameter) of hair on the chest shaved to', 'properly attach electrodes to the chest.', 'Blood sampling procedure (optional pharmacogenetic', 'Giving blood may make subjects feel faint, or experience', 'Subjects will be monitored during the blood draw for these', 'blood sample)', 'mild pain, bruising, irritation or redness at the site. In rare', 'effects and should call their study doctor if any of these', 'cases, they may get an infection', 'effects do not resolve', 'Other', 'Side effects of rescue albuterol/salbutamol. Adverse', 'Class effects associated with short acting beta-agonists', 'Subjects should call their study doctor if they experience', 'events seen in clinical studies to date are however', '(SABAs)', 'any of these symptoms', 'consistent for the beta2-adrenergic class of compounds', '24']['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', '4.6.2.', 'Benefit Assessment', 'Subjects will receive single or combination of long-acting bronchodilator therapies', 'approved for maintenance treatment of COPD. Participating subjects in this study will', 'contribute to the process of further characterizing the benefit of these long-acting', 'bronchodilators with respect to PROs and symptoms in the treatment of COPD.', 'Specific benefits associated with the study design and procedures include the following:', 'Subjects will receive treatments approved for the treatment of COPD that have', 'been shown to be effective in the population under study', 'All subjects will receive albuterol/salbutamol for use \"as needed\" for relief of', 'COPD symptoms', 'The combination of study procedures of spirometry, CAT, SGRQ, TDI, E-RS will', 'provide the study subjects with a comprehensive evaluation of their symptoms,', 'health status and COPD disease severity. Subjects will also be monitored', 'throughout the study for any worsening of COPD symptoms or decline in general', 'health. Finally smoking cessation counselling will also be provided.', '4.6.3.', 'Overall Benefit: Risk Conclusion', 'Taking into account the measures taken to minimize risk to subjects participating in this', 'study, the potential risks identified in association with UMEC/VI, UMEC, salmeterol and', 'with study procedures are justified by the anticipated benefits from active treatments that', 'may be afforded to patients with COPD.', '5.', 'SELECTION OF STUDY POPULATION AND', 'WITHDRAWAL CRITERIA', 'Specific information regarding warnings, precautions, contraindications, adverse events,', 'and other pertinent information on the GSK investigational product or other study', 'treatment that may impact subject eligibility is provided in the IBs, [GlaxoSmithKline', 'Document Number RM2006/00835/09], [GlaxoSmithKline Document Number', 'RM2009/00437/07] and product labels.', 'Deviations from inclusion and exclusion criteria are not allowed because they can', 'potentially jeopardize the scientific integrity of the study, regulatory acceptability or', 'subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.', '5.1.', 'Inclusion Criteria', 'A subject will be eligible for inclusion in this study only if all of the following criteria', 'apply:', 'AGE', '1. 40 years or older at date of signing informed consent at Screening Visit 1', '25']\n\n###\n\n", "completion": "END"}